Glaucoma is a heterogeneous
|
|
- Nathan Warner
- 5 years ago
- Views:
Transcription
1 Old and New Drug Classes Expanding To Include Glaucoma Treatments Troy Kish, PharmD, BCPS Glaucoma is a heterogeneous disease characterized by the development of increased intraocular pressure (IOP) that leads to structural changes and nerve damage within the eye. Manifestations of this disease include chronic progressive open-angle glaucoma (OAG) and acute angle-closure glaucoma (ACG), both of which may be categorized as either primary or secondary, depending on the underlying cause. 1 Glaucoma ranks among the top Dr. Kish is an Associate Professor of Pharmacy Practice at Long Island University, LIU Pharmacy (Arnold and Marie Schwartz College of Pharmacy and Health Sciences), in Brooklyn, New York. five causes of moderate to severe visual impairment and is the third leading cause of blindness worldwide. 2 Global estimates from 2013 suggest that more than 64 million people aged 40 to 80 years have either primary OAG or primary ACG, and with an increasing elderly population, that number is anticipated to reach 76 million by 2020 and million by As ACG is mainly treated through surgery, this review will focus on chronic therapies used to manage OAG. Patients with OAG often present with an elevated IOP (normal range: mmhg), however, a small subset of patients may develop ocular changes with an IOP < 21 mmhg and are referred to as having normal tension glaucoma. Conversely, some patients with an IOP > 21 mmhg do not go on to develop visual impairment and are referred to as having ocular hypertension (OHT). 4 Control of glaucoma focuses on managing the outflow of the eye s aqueous humor. The primary exit route is via the trabecular meshwork and through the Schlemm s canal, also known as conventional outflow, while outflow through the ciliary body and suprachoroidal space, known as unconventional or uveoscleral outflow, accounts for a minor amount of outflow. Topical medications represent the first line of treatment, but if IOP control is inadequate, patients may require escalation Table 1. Current FDA-Approved Medications for Glaucoma 7 Medication Class Mechanism of Action Available Products Formulations Usual Dosing Prostaglandin Reduce IOP through Xalatan (latanoprost)* 1 drop at bedtime analogs increase in outflow of Lumigan (bimatoprost)* 1 drop at bedtime aqueous humor via Travatan Z (travoprost) 1 drop at bedtime uveoscleral route Zioptan (tafluprost) Vyzulta (latanoprostene 1 drop at bedtime 1 drop at bedtime bunod) Beta blockers Reduce IOP through reduction in aqueous humor production Timoptic (timolol)* Betagan (levobunolol)* Betoptic (betaxolol)* Gel-forming solution / 1 drop twice daily 1 drop daily 1 2 drops once or twice daily 1 2 drops twice daily suspension Alpha-adrenergic Increased uveoscleral Iopidine (apraclonidine)* 1 2 drops 3 times daily agonists outflow and reduction in aqueous humor production Alphagan (brimonidine)* 1 drop 3 times daily Carbonic anhydrase inhibitors Reduces production of aqueous humor Trusopt (dorzolamide)* Diamox (acetazolamide)* Neptazane (methazolamide) Tablets and capsules Tablets 1 drop 3 times daily 250 1,000 mg daily mg 2 or 3 times daily Cholinergic agonists Causes contraction of iris sphincter, leading to increased aqueous humor outflow via trabecular meshwork IOP= intraocular pressure. *indicates available as a generic product. Pilopine (pilocarpine)* 1 drop up to 4 times daily Vol. 43 No. 8 August 2018 P&T 489
2 Table 2. Therapies for Glaucoma Currently in Late-Stage Development or Recently FDA-Approved 7 Medication Developer(s) Rhopressa (netarsudil) Aerie Pharmaceuticals Roclatan (netarsudil + latanoprost) Aerie Pharmaceuticals Bimatoprost SR Allergan OTX TP Ocular Therapeutix DE 117 Santen Mechanism Of Action Rho kinase inhibitor Rho kinase inhibitor and PGA Sustained-release PGA implant Sustained-release PGA Prostaglandin EP 2 agonist Targeted Indication/Population Patients with ocular hypertension or glaucoma and IOP < 26 mmhg or glaucoma and glaucoma and glaucoma Adults with ocular hypertension or glaucoma; Patients with poor response to other PGA Route and Dose Once-daily 0.02% eye drop Once-daily netarsudil 0.02%/ latanoprost 0.005% eye drop Ocular implant injected every 6 months Canalicular implant inserted every 90 days Once-daily eye drop Expected Price Strategy Equivalent to average PGA price with a 10% discount Current AWP: $274 per 2.5 ml 5 Equivalent to average PGA with 10% premium ACOT of Lumigan with 5% premium ACOT of Travatan with 5% premium Equivalent to branded PGA with a 10% premium Anticipated Launch Date(s) Approved in US: Dec EU: 2018 Japan: 2021 US: EU: 2020 Japan: 2022 US: EU: 2022 US: EU: 2021 US: EU: 2022 Japan: 2019 ACOT= annual cost of therapy; AWP = average wholesale price; IOP= intraocular pressure; PGA = prostaglandin analog; US = United States; 5EU = France, Germany, Italy, Spain, United Kingdom. to laser-based therapies or surgical procedures. 4 Several classes of medications are available to treat OAG, but the recommended initial therapy is with a medication from either the beta blocker or prostaglandin analog classes. 4 Prostaglandin analogs work by increasing aqueous humor outflow through the uveoscleral pathway. Beta blockers are believed to act by reducing the production of aqueous humor. A brief overview of the various classes of medications and products available in the United States is provided in Table 1. The usual treatment goal is to achieve a 25% 30% reduction from the patient s baseline IOP, but other factors such as baseline IOP, pre-existing nerve damage, risk for disease progression, or development of adverse effects may prompt providers to pursue more aggressive or lenient therapeutic goals. 1 Patients may require multiple eye drops from different classes in order to achieve the IOP goal. Despite the number of effective medications and readily available generic and combination products, there remains a need for new and innovative therapies. One key area for improvement is patient adherence. A survey of patients with glaucoma revealed a number of barriers that prevent effective disease management, including difficulty with effective administration of eye drops, poor medication and disease education, and nonadherence with complex dosing regimens. 6 Some treatments discussed below seek to address adherence through the use of innovative delivery methods that prolong medication activity. Physicians also desire therapies with novel mechanisms that are able to lower IOP more effectively and medications that could provide protection against ocular nerve degeneration. 7 Below (and summarized in Table 2) is a brief overview of several new agents, in no particular order, that have recently been approved or are poised to enter the market in the coming years. Rhopressa (netarsudil ophthalmic solution) In December of 2017, the Food and Drug Administration (FDA) approved netarsudil, the first of a new class of medications known as Rho kinase (ROCK) inhibitors. In addition to inhibiting ROCK, this medication also possesses other IOP-lowering mechanisms, such as the inhibition of norepinephrine transport and an ability to reduce episcleral venous pressure. 7,8 The double-blind, randomized, multicenter trial ROCKET-1 (N=411) compared the efficacy of netarsudil 0.02% dosed once daily at nighttime with timolol maleate 0.5% dosed twice daily. The ROCKET-2 trial (N=756) had a similar design, with an additional netarsudil 0.02% twice-daily dosing arm. Both trials followed patients with OHT or OAG who had an IOP of > 20 mmhg and < 27 mmhg for three months. The primary endpoint in both trials was a reduction in IOP. In ROCKET-1, patients with a baseline IOP < 27 mmhg who received netarsudil demonstrated a 15% 22% reduction in IOP as compared with a 17% 22% reduction in patients who received timolol, but this was not sufficient to demonstrate noninferiority based on prespecified criteria. A posthoc analysis that focused on patients whose baseline IOP was < 25 mmhg was able to demonstrate noninferiority. 9 ROCKET-2 s primary efficacy population focused on patients with an IOP < 25 mmhg and was able to demonstrate mean reductions of mmhg and mmhg in patients receiving daily and twice-daily netarsudil, respectively. These reductions were similar to those seen with twice-daily timolol, which produced a mmhg reduction from baseline and demonstrated the noninferiority of 490 P&T August 2018 Vol. 43 No. 8
3 netarsudil. In terms of percent reduction in IOP, daily netarsudil was able to achieve a 16% 21% reduction, while twice-daily dosing showed a 22% 24% reduction; twice-daily timolol demonstrated an 18% 23% reduction. 9 The use of netarsudil appears to be generally well tolerated, with the most common observed adverse effect being conjunctival hyperemia (50% 53%), followed by conjunctival hemorrhage (13% 15%), and cornea verticillata (5% 9%). Other adverse effects including blurred vision, eye pain or erythema, and erythema of the eyelid, were also noted in > 5% of patients. 9 Aerie Pharmaceuticals also conducted the ROCKET-4 trial to demonstrate the sixmonth safety of netarsudil. Results from this trial, released in April 2017, showed daily netarsudil to be non-inferior to twice-daily timolol. The frequency and severity of effects were seen at similar rates to those in the ROCKET-1 and ROCKET-2 trials. 10 The entry of netarsudil into the market is exciting as it is a novel, well tolerated, once-daily agent. One limiting factor to this medication is its reduced efficacy in patients with a baseline IOP of 26 mmhg or higher. As Aerie Pharmaceuticals has already obtained approval in the United States, it is anticipated to launch in 2019 in the European Union and in 2021 in Japan. 7 Roclatan (netarsudil/latanoprost ophthalmic solution) Roclatan, a combination product containing netarsudil and the prostaglandin analog latanoprost, is also being developed by Aerie Pharmaceuticals. This fixed-dose combination would be administered as a once-daily eye drop in the evening and is formulated as a netarsudil/latanoprost 0.02%/0.005% solution. The IOP-lowering effects of netarsudil are expected to be complemented by increased outflow by way of the uveoscleral pathway, facilitated by latanoprost. 7 The Mercury 1 trial randomized 718 subjects into three treatment arms: netarsudil monotherapy, latanoprost monotherapy, or netarsudil/latanoprost combination therapy, each dosed once daily. The primary efficacy outcome was mean IOP at three months; patients were observed for 12 months for ocular and systemic safety outcomes. At 90 days, patients who received the combination therapy achieved mmhg lower mean IOP than patients who received latanoprost monotherapy, and mmhg lower mean IOP than patients who received netarsudil monotherapy. Significantly more subjects receiving combination therapy demonstrated a 20% or greater IOP reduction and achieved an IOP of < 18 mmhg. While no serious adverse events were reported, a higher percentage of patients discontinued therapy at three months in the combination (15.5%) and netarsudil monotherapy (17.6%) arms versus latanoprost monotherapy (5.5%), with adverse effects being cited as the most common reason for discontinuation. Conjunctival hyperemia was reported in approximately 50% of patients, with most cases being described as mild. Approximately 5% to 11% of patients reported experiencing conjunctival hemorrhage, pruritus, increased lacrimation, and cornea verticillata. 11 The Mercury 2 trial evaluated changes in IOP at 90 days in 750 participants receiving netarsudil/latanoprost, netarsudil monotherapy, or latanoprost monotherapy. Similar to the Mercury 1 findings, the combination agent was able to lower IOP an additional mmhg compared with latanoprost monotherapy and an additional mmhg when compared with netarsudil monotherapy. Fifty-six percent of patients receiving netarsudil/latanoprost were able to achieve a diurnal IOP of < 16 mmhg. 12 An additional clinical trial (Mercury 3) is underway to compare the safety and efficacy of netarsudil/latanoprost with that of the combination bimatoprost/ timolol 0.03%/0.5%. This trial, which is still recruiting patients, will aim to enroll 472 participants and evaluate changes in IOP at six months in addition to clinical safety endpoints. Currently, no additional information is available regarding this study, but the anticipated completion date is April Aerie Pharmaceuticals filed a New Drug Application on May 15, 2018 and expects a decision from the FDA within 10 months. 14 OTX TP Ocular Therapeutix is developing a bioresorbable canalicular implant that will continuously deliver the prostaglandin analog travoprost for up to 90 days. The active medication is encapsulated in a biodegradable polyethylene-glycol hydrogel that will swell upon implantation to retain its position in the eye. 15 This plug is inserted through noninvasive methods by a specialist and does not require removal as it exits through the nasolacrimal system. 7 This novel delivery system addresses the major issue of poor patient adherence and is poised to be the first of several implantable therapies to enter the major markets. 7 A phase 2b study evaluated efficacy and safety of a punctum plug of travoprost against timolol maleate 0.5% drops twice daily in 79 patients. Participants were enrolled if they had a diagnosis of OHT or OAG with a mean baseline IOP of 24 mmhg at Hour 0 and an IOP of 22 mmhg when checked 4 and 8 hours later. Mean reductions in IOP were evaluated at 30, 60, and 90 days at multiple times each day (8 a.m., 12 p.m., and 4 p.m.). Patients in both groups demonstrated a reduction in IOP from baseline, although those receiving OTX TP showed a mmhg reduction while those receiving timolol experienced a mmhg reduction. These reductions in IOP were observed at all time points throughout the day. The reported rates of ocular (39.4% vs. 37.5%) and nonocular (9.1% vs. 7.5%) adverse effects were similar in the OTX TP and timolol arms, respectively. The most common adverse effects were dacryocanaliculitis (12.1% vs. 10%), acquired dacryostenosis (6.1% vs. 5%), eyelid edema (6.1% vs. 0%) and scar (6.1% vs. 0%) in the OTX TP and timolol groups, respectively. 16 Ocular Therapeutix is now enrolling patients for a phase 3, placebocontrolled trial evaluating the efficacy and safety of OTX TP in the treatment of OAG or OHT. This trial will aim to enroll 550 patients with a primary endpoint of changes in IOP at Weeks 2, 6, and 12, at 8 a.m., 10 a.m., and 4 p.m. Ocular Therapeutix expects to complete this trial in December While OTX TP has the advantage of a noninvasive route of administration and is likely to be the first long- Vol. 43 No. 8 August 2018 P&T 491
4 acting implant to enter the market, the lower impact on IOP as compared with timolol drops observed in the phase 2b trial and lack of active control in the upcoming phase 3 trial may make some providers unsure of its place in therapy. Bimatoprost Sustained-Release Ocular Implant Allergan is reformulating its prostaglandin analog, bimatoprost, into a sustained-release ocular implant as a way to enhance patient adherence. Bimatoprost SR would continuously deliver medication over six months after being inserted via injection into the anterior chamber of the eye through a noninvasive procedure. 7 A phase 1/2 prospective, dose-ranging trial that examined 75 patients with OAG demonstrated a rapid and sustained lowering of IOP with bimatoprost SR. Following a washout period, enrollees intracamerally received various doses in the study eye while the other eye was treated with topical bimatoprost 0.03%. Overall mean IOP reductions of 7.2, 7.4, 8.1, and 9.5 mmhg were seen in patients receiving 6, 10, 15, and 20 mcg of bimatoprost SR, respectively, as compared with an 8.4 mmhg reduction with topical bimatoprost. Patients initially reported higher rates of adverse effects such as eye pain, foreign body sensation in the eye, and conjunctival hemorrhage with bimatoprost SR but these symptoms subsided within two days of onset. Following Day 2, the eye receiving bimatoprost SR had less reported conjunctival hyperemia (6.7% vs. 17.3%) than the eye receiving topical bimatoprost, while reports of other adverse effects remained similar between the eyes. When questioned at Day 8, 79.7% of patients reported the procedure to be less burdensome than anticipated and, at Week 12, 77% of patients were very or extremely likely to have another implant procedure. 18 An ongoing phase 3 trial enrolling 594 patients with OAG or OHT is comparing twice-daily timolol drops to two undisclosed doses of bimatoprost SR administered on Day 1, at Week 16, and at Week 32. The primary outcome will be changes in IOP from baseline to Week 12; however, patients will continue to be followed for a 12-month 492 P&T August 2018 Vol. 43 No. 8 treatment duration plus an additional eight-month extended follow-up. 19 A second trial, similarly designed, is aiming to enroll 600 patients and has an estimated primary completion date of March Two additional trials are comparing bimatoprost SR with selective laser trabeculoplasty in patients with OAG or OHT who are unable to be controlled with topical IOP-lowering therapies. In these trials, an undisclosed dose of bimatoprost SR will be administered on Day 1, at Week 16, and at Week 32. The primary outcome will be changes in IOP at Week 24. Investigators seek to enroll 160 patients for each study and have estimated primary completion dates of November 2019 and May ,22 DE-117 Santen Pharmaceutical is developing a novel agent that acts on a new target in the prostaglandin pathway, the prostaglandin EP 2 receptor. While other prostaglandin analogs bind to the F2-alpha receptor, DE-117 activates the EP 2 receptor and is thought to lower IOP by regulating outflow through the conventional pathways. 23 This novel mechanism may position DE-117 to be a viable option in patients for whom other prostaglandin analogs have not adequately lowered IOP. In November 2017, Santen filed for approval of DE-117 in Japan while continuing to conduct trials in other markets. 24 There are several clinical trials involving DE-117 for which enrollment is complete but results have not yet been posted. Among these trials: The phase 2 SEE-1 trial, evaluating five doses of DE-117 against latanoprost among 184 participants in several centers across the United States, was listed as having completed enrollment as of April ; a long-term, open-label trial known as RENGE, involving 125 patients and that compared two groups of DE-117 monotherapy with patients receiving the combination DE-117 and timolol ophthalmic solution, was listed as having been completed in November , and the AYAME study, which also evaluated two doses of DE-117 against a placebo arm as well as a latanoprost arm in 253 patients with OAG and OHT. 27 One trial for which results are available evaluated four varying concentrations of DE-117 against placebo and latanoprost in 91 patients. At the end of 4 weeks, investigators found that a concentration of 0.002% of DE-117 performed the best and matched the IOPlowering effect of latanoprost. The most commonly observed adverse effects in the 0.002% dosing arm, all seen in approximately 14% of patients, included conjunctival and ocular hyperemia, photophobia, and eye pain. 28 The only trial listed as recruiting patients is a phase 3 trial comparing DE-117 directly to latanoprost in patients with OAG or OHT in an anticipated 360 patients. The primary outcome is mean diurnal IOP at three months, and the expected completion date is November CONCLUSION Several other long-acting formulations of established medications are in the early stages of development, which suggests that addressing the issue of poor patient adherence is an area of keen interest. In addition, new medications belonging to established classes, such as prostaglandin analogs, are in early development, as are new therapeutic classes such as guanylate cyclase activators. 7 With these novel treatment options on the horizon, better management of glaucoma looks promising for the near future. REFERENCES 1. Jonas JB, Aung T, Bourne RR, et al. Glaucoma. Lancet 2017;390(10108): Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment : a systematic review and meta-analysis. Lancet Glob Health 2017;5(12):e1221 e Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11): Fingeret M, Mancil GL, Bailey IL, et al. Optometric clinical practice guideline care of the patients with open angle glaucoma. American Optometric Association. Revised org/documents/optometrists/cpg-9.pdf. 5. Red Book Online. Ann Arbor, MI: Truven Health Analytics. Accessed May 30, Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research continued on page 502
5 continued from page 492 study. Eye 2009;23(4): Pharmapoint: Glaucoma Global drug forecast and market analysis to New York, NY: GlobalData; December Rhopressa (netarsudil) [prescribing information]. Irvine, CA; Aerie Pharmaceuticals. December Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol 2018;186: Aerie Pharmaceuticals. Aerie pharmaceuticals reports positive ROCKET-4 sixmonth topline safety and efficacy results for Rhopressa (netarsudil ophthalmic solution) 0.02%. Press release. April 12, static-files/7c d3-48ce-aec e4de1df. 11. Aerie Pharmaceuticals. Roclatan Mercury 1 phase 3 topline results. July 20, static-files/f4a8a03c-e34e db- 5b5d17e2bd Aerie Pharmaceuticals. Aerie Pharmaceuticals reports positive Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% phase 3 topline efficacy results. May 24, aeriepharma.com/static-files/23eefae d ec6f3f1dbd6. Accessed 13. ClinicalTrials.gov. Safety and efficacy study PG324 (netarsudil/latanoprost 0.02%/0.005%) ophthalmic solution compared to GANFORT ophthalmic solution in open angle glaucoma or ocular hypertension. Updated June 12, study/nct ?term=mercury- 3&cond=netarsudil&rank=1. Accessed 14. Aerie Pharmaceuticals. Aerie Pharmaceuticals submits new drug application to U.S. Food and Drug Administration for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%. Press release. May 15, aeriepharma.com/news-releases/newsrelease-details/aerie-pharmaceuticalssubmits-new-drug-application-us-foodand O Connor M, Blizzard CD, Bassett M, et al. In vitro/in vivo correlation of travoprost release from a biodegradable hydrogel punctum plug for the treatment of glaucoma. Invest Ophthalmol Vis Sci 2014;55: Wilson C, Sall K, Bafna S, et al. Results of a randomized, double-masked, parallel-arm phase 2b study evaluating the safety and efficacy of OTX-TP (travoprost insert) compared to timolol drops for the treatment of patients with open-angle glaucoma or ocular hypertension. Presented at the Association for Research and Vision and Ophthalmology 2017 Annual Meeting, Baltimore, MD. OTX-TP_Phase_2b.pdf. Accessed July 12, ClinicalTrials.gov. OTX : A phase 3 study evaluating the safety and efficacy of OTX-TP in subjects with open angle glaucoma and ocular hypertension. Updated September 14, gov/ct2/show/nct ?term=o TX+%E2%80%93+TP&rank=3. Accessed 18. Lewis RA, Christie WC, Day DG, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6 month-results from a phase I/II clinical trial. Am J Ophthalmol 2017;175: ClinicalTrials.gov. Efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. Updated March 8, show/nct Accessed July 12, ClinicalTrials.gov. Safety and efficacy of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. Updated February 9, show/record/nct ?term=bim atoprost+sr&rank=3. Accessed July 12, ClinicalTrials.gov. A comparison of bimatoprost SR to selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension. Updated September 5, gov/ct2/show/nct ?term=bi matoprost+sr&rank=1. Accessed July 12, ClinicalTrials.gov. Comparison of bimatoprost SR to selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension. Updated September 8, show/nct ?term=bimatoprost+ SR&rank= Wang JW, Woodward DF, Stamer WD. Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow. Invest Ophthalmol Vis Sci 2013;54(7): UBE Industries. Santen files for manufacturing and marketing approval of glaucoma and ocular hypertension drug candidate DE-117. November 27, news/2017/ _01.html. Accessed 25. ClinicalTrials.gov. Multi-center phase II study assessing the safety and efficacy of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension (SEE-1). Updated April 18, ct2/show/nct ?term=de- 117&rank= ClinicalTrials.gov. A long-term study of DE-117 ophthalmic solution monotherapy and concomitant use of DE-117 ophthalmic solution with timolol ophthalmic solution in patients with OAG or OH: RENGE Study. Updated November 20, NCT ?term=DE-117&rank= ClinicalTrials.gov. A study assessing the efficacy and safety of DE-117 ophthalmic solution in subjects with primary open angle glaucoma or ocular hypertension --AYAME study. Updated November 20, gov/ct2/show/nct ?term=de- 117&rank= Ihekoromadu N, Lu F, Iwamura R, et al. Safety and efficacy of DE-117, a selective EP 2 agonist in a phase 2a study. Invest Ophthalmol Vis Sci 2015;56(7): ClinicalTrials.gov. Phase III study assessing the safety and efficacy of DE-117 ophthalmic solution compared with latanoprost ophthalmic solution in subjects with OAG or OHT. Updated January 30, NCT ?term=DE-117&rank=3. n 502 P&T August 2018 Vol. 43 No. 8
Treatments on the Horizon
Latanoprostene bunod (Vesneo) Treatments on the Horizon Dominick L Opitz, OD, FAAO Associate Professor Illinois College of Optometry Valeant (B+L) Nitrous oxide-donating prostaglandin F2-alpha analogue
More informationBuilding a Major Ophthalmic Pharmaceutical Company. Aerie Pharmaceuticals, Inc. Company Overview June 2-3, 2015
Building a Major Ophthalmic Pharmaceutical Company Aerie Pharmaceuticals, Inc. Company Overview June 2-3, 2015 1 Important Information Any discussion of the potential use or expected success of our product
More informationRoclatan TM Mercury 1 Phase 3 12-month Topline Results. For Investor Use
Roclatan TM Mercury 1 Phase 3 12-month Topline Results For Investor Use 1 Important Information Any discussion of the potential use or expected success of our product candidates is subject to our product
More informationClass Update with New Drug Evaluation: Glaucoma Drugs
Class Update with New Drug Evaluation: Glaucoma Drugs Date of Review: May 2018 Date of Last Review: January 2015 End Date of Literature Search: 02/26/2018 Generic Name: latanoprostene bunod Brand Name
More informationClass Update with New Drug Evaluation: Glaucoma Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAerie Pharmaceuticals, Inc. Additional Rhopressa Rocket 1 Analyses and Path Forward
Aerie Pharmaceuticals, Inc. Additional Rhopressa Rocket 1 Analyses and Path Forward May 7, 2015 1 Important Information Any discussion of the potential use or expected success of our product candidates
More informationVolume 9; Number 6 May 2015 PRESCRIBING FOR CHRONIC OPEN ANGLE GLAUCOMA (COAG) AND OCULAR HYPERTENSION (OHT)
Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire
More informationRoclatan TM Mercury 2 Phase 3 Topline Results
Roclatan TM Mercury 2 Phase 3 Topline Results 1 Important Information Any discussion of the potential use or expected success of our product candidates is subject to our product candidates being approved
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 May 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 May 2008 COSOPT 20 mg/5 mg/ml, eye drops, solution in single dose container Box of 60 0.2 ml single dose containers
More informationVI.2.2 Summary of treatment benefits
EU-Risk Management Plan for Bimatoprost V01 aetiology), both OAG and ACG can be secondary conditions. Secondary glaucoma refers to any case in which another disorder (e.g. injury, inflammation, vascular
More informationFinancial Disclosure. Prostaglandin Analogs (PGs) The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy
The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy Danica J. Marrelli, OD, FAAO University of Houston College of Optometry Financial Disclosure I have received I have received speaking
More informationBrightFocus Foundation is the new name for American Health Assistance Foundation.
In this section, you will find the following: Glaucoma Medications Laser Therapies Conventional Surgical Procedures In the second section, you will find information on how to search for potential treatments
More informationClass Update with New Drug Evaluation: Glaucoma Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTreatments for Open-Angle Glaucoma. A Review of the Research for Adults
Treatments for Open-Angle Glaucoma A Review of the Research for Adults Is This Information Right for Me? Yes, this information is for you if: Your eye doctor has said that you have open-angle glaucoma,
More informationAbbreviated Update: Ophthalmic Glaucoma Agents
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Abbreviated Update: Ophthalmic Glaucoma Agents Month/Year
More informationA. Incorrect! Acetazolamide is a carbonic anhydrase inhibitor given orally or by intravenous injection.
Pharmacology - Problem Drill 20: Drugs that Treat Glaucoma Question No. 1 of 10 1. is a topical carbonic anhydrase inhibitor. Question #01 (A) Acetazolamide (B) Clonidine (C) Dorzolamide (D) Apraclonidine
More informationUpdate on Glaucoma Medical Therapy
Update on Glaucoma Medical Therapy Murray Fingeret, OD Disclosures Consultant Alcon, Allergan, Bausch & Lomb, Carl Zeiss Meditec, Dyopsys, Heidelberg Engineering, Reichert, Topcon Glaucoma Therapy An Overview
More informationBuilding a Major Ophthalmic Pharmaceutical Company. Aerie Pharmaceuticals, Inc. July 13, 2016
Building a Major Ophthalmic Pharmaceutical Company Aerie Pharmaceuticals, Inc. July 13, 2016 1 Important Information Any discussion of the potential use or expected success of our product candidates is
More informationRhopressa TM Rocket 2 Phase 3 Topline Results
Rhopressa TM Rocket 2 Phase 3 Topline Results 1 Important Information Any discussion of the potential use or expected success of our product candidates is subject to our product candidates being approved
More informationUpdate on Rhopressa TM QD (netarsudil ophthalmic solution) 0.02% and Roclatan TM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.
Update on Rhopressa TM QD (netarsudil ophthalmic solution) 0.02% and Roclatan TM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 1 Important Information Any discussion of the potential use or
More informationCompany Overview. Investor Presentation March 2018
Company Overview Investor Presentation March 2018 Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing
More informationSouth East London Area Prescribing Committee Chronic Open Angle Glaucoma and Ocular Hypertension Treatment Pathway
Proceed to 2 nd line treatment if further reduction in IOP required and there is good response to PGAs or (& no South East London Area Prescribing Committee Chronic Open Angle Glaucoma and Ocular Hypertension
More informationCompleted Clinical Research Trials Monte Dirks, M.D.
Completed Clinical Research Trials Monte Dirks, M.D. Monte Dirks, M.D. - Primary Investigator Norfloxacin -Merck (1986) Safety and efficacy of norfloxacin vs. tobramycin in the treatment of external ocular
More informationManaging the Patient with POAG
Managing the Patient with POAG Vision Institute Annual Fall Conference Mitchell W. Dul, OD, MS, FAAO mdul@sunyopt.edu Richard J. Madonna, MA, OD, FAAO rmadonna@sunyopt.edu Ocular Hypertension (OHT) Most
More informationCompany Overview. Investor Presentation November 2018
Company Overview Investor Presentation November 2018 Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing
More informationEast and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults
East and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults Introduction Glaucoma is a group of eye diseases causing optic nerve damage. In most cases
More informationLong Term Care Formulary RS 14. RESTRICTED STATUS Topical Medical Treatment of Glaucoma 1 of 5
RESTRICTED STATUS Topical Medical Treatment of Glaucoma 1 of 5 PREAMBLE Significance: Glaucoma occurs in 1-2% of white people aged over 40 years, rising to 5% at 70 years and exponentially with advancing
More informationVision Health: Conditions, Disorders & Treatments GLAUCOMA
Vision Health: Conditions, Disorders & Treatments GLAUCOMA Glaucoma is a disease of the optic nerve, which transmits the images you see from the eye to the brain. The optic nerve is made up of many nerve
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
Guidelines for the medical treatment of chronic open angle glaucoma and ocular hypertension Summary: DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Diagnosis and management of ocular hypertension (OHT)
More informationInnovations in Glaucoma Drug Delivery What the Future Holds. Justin Schweitzer, OD, FAAO Vance Thompson Vision Sioux Falls, South Dakota
Innovations in Glaucoma Drug Delivery What the Future Holds Justin Schweitzer, OD, FAAO Vance Thompson Vision Sioux Falls, South Dakota Allergan Glaukos Bausch and Lomb Bio- Tissue Alcon TearScience Reichert
More informationCourse # Glaucoma Pearls: From OGS to ARVO
Course # 101 DISCLOSURE STATEMENT Consultant-Aerie, Allergan, B + L, Carl Zeiss Meditec, Heidelberg Engineering, Novartis Pharma, Topcon Course Title: Lecturer: Glaucoma Pearls: From OGS to ARVO Murray
More informationWhat s New in Glaucoma Treatment! (TPG)
What s New in Glaucoma Treatment! (TPG) Jane Kuo,OD Author: Dr. Jane Kuo graduated from the Southern California College of Optometry at Marshall B. Ketchum University (SCCO). She completed her residency
More informationOcular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study
Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study James H. Peace, M.D. 1, Casey K. Kopczynski, Ph.D. 2, and Theresa Heah, M.D. 2 1 Inglewood, CA 2
More information(Eye)Drop It Like It s Hot New & Exciting Advancements in Glaucoma
Disclosures (Eye)Drop It Like It s Hot New & Exciting Advancements in Glaucoma I have no financial ties or relationships to any of the companies or products mentioned in this lecture. Although if one wants
More informationGlaucoma Disease Progression Role of Intra Ocular Pressure. Is Good Enough, Low Enough?
Glaucoma Disease Progression Role of Intra Ocular Pressure Is Good Enough, Low Enough? Glaucoma Diseases Progression Key Considerations Good number of patients may be diagnosed only after some damage the
More informationAbbreviated Class Update: Ophthalmics, Glaucoma agents. Month/Year of Review: August 2012 End date of literature search: June 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOCULAR PHARMACOLOGY GLAUCOMA. increased intraocular pressure. normally mm Hg. when to Tx no fixed level.
OCULAR PHARMACOLOGY GLAUCOMA increased intraocular pressure normally 12 20 mm Hg. when to Tx no fixed level. literature sets ~21 mm Hg as upper limit of normal. some safe at 30 mm Hg some may have damage
More information3/31/2019. Role of IOP. Role of IOP. Role of IOP. Role of IOP. Evaluation of glaucoma has changed Why hasn t treatment?
Glaucoma Update ROLE FOR RHOPRESSA Gregory D. Searcy, M.D. 1857: German ophthalmologist Albrecht Van Graefe concluded all glaucomatous optic disc excavation is associated with high IOP based on the only
More informationCollaboration in the care of glaucoma patients and glaucoma suspects. Barry Emara MD FRCS(C) Nico Ristorante November 29, 2012
Collaboration in the care of glaucoma patients and glaucoma suspects Barry Emara MD FRCS(C) Nico Ristorante November 29, 2012 Goals of Collaboration Patient-centred and evidence based approach Timely access
More informationIOP measurements: 8.00 am (trough drug levels) and am (peak drug levels)(2 hours post dose)
This overview of 2% eye drops was presented by Dr. Ravin N. Das, at Hotel Satya Ashoka, on 19-6-2004 in place of Dr. H. S. Ray due to unforseen circumstances. This dinner meeting was sponsored by Cipla
More informationTransforming Glaucoma Care with OTX-TP Sustained Release Travaprost Plug
Transforming Glaucoma Care with OTX-TP Sustained Release Travaprost Plug Jonathan H. Talamo, M.D. Chief Medical Officer Glaucoma 360 January 29, 2016 Page 1 Forward-Looking Statements Any statements in
More informationPGAs. Glaucoma Pharmacology A-Z. Selecting Therapy. PGAs Prostaglandin analogs. Prostaglandin Side Effects 1/6/2014
PGAs Glaucoma Pharmacology A-Z Eric E. Schmidt, O.D. Omni Eye Specialists Wilmington, NC schmidtyvision@msn.com QHS dosing Long duration of action Flatten diurnal curve Effective on trough and peak IOP
More informationGlaucoma Pharmacology A-Z
GLAUCOMA PHARMACOLOGY A-Z ERIC E. SCHMIDT, O.D., F.A.A.O. Building-block approach to medical therapy Establish the strongest foundation prior to resorting to adjunctive therapy OMNI EYE SPECIALISTS WILMINGTON,
More informationMedical Treatment in Pediatric Glaucoma
Medical Treatment in Pediatric Glaucoma By Nader Bayoumi, MD Lecturer of Ophthalmology Ophthalmology Department Alexandria University Alexandria, Egypt ESG 2012 Pediatric glaucoma is a surgical disease
More informationAR CS205 Clinical Pilot Study Topline Results
AR-13324-CS205 Clinical Pilot Study Topline Results 1 Important Information The information in this presentation is current only as of its date and may have changed or may change in the future. We undertake
More informationTrends In The Utilization of Antiglaucoma Medication: An Analysis of Canadian Drug Insurance Claims
Western University Scholarship@Western Electronic Thesis and Dissertation Repository April 2014 Trends In The Utilization of Antiglaucoma Medication: An Analysis of Canadian Drug Insurance Claims Kwun
More information7/25/2018 GLAUCOMA: YOU MAKE THE CALL GLAUCOMA: YOU MAKE THE CALL. Please text us your questions! PACHYMETRY
GLAUCOMA: YOU MAKE THE CALL Lori Vollmer, OD Jessica Steen, OD Greg Caldwell, OD Joseph Sowka, OD GLAUCOMA: YOU MAKE THE CALL Please text us your questions! Joe: 954-298-0970 Greg: 814-931-2030 PACHYMETRY
More informationEfficacy of latanoprost in management of chronic angle closure glaucoma. Kumar S 1, Malik A 2 Singh M 3, Sood S 4. Abstract
Original article Efficacy of latanoprost in management of chronic angle closure glaucoma Kumar S 1, Malik A 2 Singh M 3, Sood S 4 1 Associate Professor, 2 Assistant Professor, 4 Professor, Department of
More informationEXAMINING PATIENT-PHYSICIAN COMMUNICATION REGARDING COST IN THE GLAUCOMA PATIENT POPULATION
EXAMINING PATIENT-PHYSICIAN COMMUNICATION REGARDING COST IN THE GLAUCOMA PATIENT POPULATION Catherine Slota A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Epidemiology of the disease Incidence and prevalence Increased pressure in the eye occurs in more than 100 million people, and
More informationROBERT L. SHIELDS, M.D. GLAUCOMA SURGERY AND TREATMENT
1 CURRICULUM VITAE ROBERT L. SHIELDS, M.D. GLAUCOMA SURGERY AND TREATMENT University of Colorado Health Eye Center Cherry Creek 2000 South Colorado Boulevard Annex Building, Suite 100 Denver, Colorado
More informationGlaucoma Clinical Update. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012
Glaucoma Clinical Update Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Objectives Understand the different categories of glaucoma Recognize the symptoms and signs of open angle and angle-closure
More informationA Short-term Study of the Additive Effect of Latanoprost 0.005% and Brimonidine 0.2%
A Short-term Study of the Additive Effect of Latanoprost 0.005% and Brimonidine 0.2% Haydar Erdoğan, İlker Toker, Mustafa Kemal Arıcı, Ahmet Aygen and Ayşen Topalkara Department of Ophthalmology, School
More informationJuly 2016 Corporate Presentation. DAVID P. SOUTHWELL, President and CEO Cantor Fitzgerald 2 nd Annual Health Care Conference
July 2016 Corporate Presentation DAVID P. SOUTHWELL, President and CEO Cantor Fitzgerald 2 nd Annual Health Care Conference Forward Looking Statements This presentation contains forward-looking statements
More informationContinuing Education
Continuing Education Glaucoma: Overview & Treatment Options Authors: Tyler Rinker, Pharm.D. Harrison School of Pharmacy, Auburn University Mary Elizabeth Terrell, Pharm.D. Harrison School of Pharmacy,
More informationSummary of the risk management plan (RMP) for Izba (travoprost)
EMA/14138/2014 Summary of the risk management plan (RMP) for Izba (travoprost) This is a summary of the risk management plan (RMP) for Izba, which details the measures to be taken in order to ensure that
More informationHighlights from AGS: New Surgical Devices,
SEARCH OIS... Keeping an Eye on Innovation Through Breaking News in Ophthalmology. Highlights from AGS: New Surgical Devices, Novel Therapeutics March 9, 2016 By Michelle Dalton Share 0 Share 4 Tweet Share
More informationSponsor. Generic Drug Name. Trial Indications. Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Reason for Termination
Sponsor Alcon Research, Ltd. Generic Drug Name Travoprost/timolol maleate Trial Indications Open-angle glaucoma or ocular hypertension Protocol Number C-09-007 Protocol Title An Evaluation of Patient Reported
More informationThe second most common causes of blindness worldwide. ( after cataract) The commonest cause of irreversible blindness in the world Estimated that 3%
The second most common causes of blindness worldwide. ( after cataract) The commonest cause of irreversible blindness in the world Estimated that 3% of our population age > 40 have glaucoma In the past:
More information27% Contributions to the World s Glaucoma Patients. Feature million people
Feature Contributions to the World s Glaucoma Patients Santen will fully harness our strengths as a specialized pharmaceutical company to contribute to patients being identified early and receiving treatment
More informationPatients with ocular hypertension or
... REPORTS... An Economic Analysis of Switching to Latanoprost from a β-blocker or Adding Brimonidine or Latanoprost to a β-blocker in Open-Angle Glaucoma or Ocular Hypertension William C. Stewart, MD;
More informationDisclosures. What is glaucoma? Prevalence studies. Types of glaucoma 3/21/2016. Pinakin G Davey PhD, OD, FAAO. Professor and Director of Research
Disclosures Pinakin G Davey PhD, OD, FAAO Professor and Director of Research Principal investigator for ivue OCT trial Principal investigator Topcon FDA trials for Maestro and OCT 2000 Consultant for Topcon
More informationKeeping Current in Glaucoma Surgery
Keeping Current in Glaucoma Surgery #51596-GL COPE April 2018 Ilya Rozenbaum, MD Matossian Eye Associates Financial Disclosures Alcon Allergan B+L Glaukos Human Cost of Glaucoma Glaucoma is the second
More informationDrug Prescribing Pattern & Adverse Drug Effects Of Anti Glaucoma Medication for Primary Glaucoma at Tertiary Care Hospital
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 11 Ver. III (Nov. 2017), PP 36-41 www.iosrjournals.org Drug Prescribing Pattern & Adverse Drug
More informationGlaucoma: target intraocular pressures and current treatments James McAllister FRCS, FRCOphth
Glaucoma: target intraocular pressures and current treatments James McAllister FRCS, FRCOphth Skyline Imaging Ltd Our Drug review of glaucoma management describes the use of target intraocular pressures
More information5/12/2014. Lynn E. Lawrence, CPOT, ABOC, COA
Lynn E. Lawrence, CPOT, ABOC, COA Glaucoma is an optic neuropathy characterized by a loss of ganglion cells and their axons, in the RNFL. The loss of retinal ganglion cells in glaucoma is irreversible
More informationClass Update: Ophthalmic Glaucoma Agents
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Ophthalmic Glaucoma Agents Month/Year
More informationGLAUCOMA (2006) PHILIPPINE GLAUCOMA SOCIETY
GLAUCOMA (2006) PHILIPPINE GLAUCOMA SOCIETY CPM 9 TH EDITION Philippine Glaucoma Society (PGS) Correspondence to: Eye Referral Center, T. M. Kalaw Street, Ermita, Manila Telephone: 524-7119/525-9360 Mobile:
More informationPRESSURE MATTERS NEW THERAPIES IN THE MEDICAL MANAGEMENT OF GLAUCOMA
CE MONOGRAPH PRESSURE MATTERS NEW THERAPIES IN THE MEDICAL MANAGEMENT OF GLAUCOMA Visit http://tinyurl.com/manageglaucomace for online testing and instant CE certificate FACULTY MICHAEL CHAGLASIAN, OD
More informationPhase 3c Topline Results. Page 1
Phase 3c Topline Results Page 1 Important Information Any statements in this presentation about future expectations, plans and prospects for the Company including the development and regulatory status
More informationCHARTING THE NEW COURSE FOR MIGS
CHARTING THE NEW COURSE FOR MIGS SEE WHAT S ON THE HORIZON CyPass Micro-Stent the next wave in micro-invasive glaucoma surgery. MICRO-INVASIVE GLAUCOMA SURGERY (MIGS) OFFERS A REVOLUTIONARY APPROACH TO
More informationChronicity. Narrow Minded. Course Outline. Acute angle closure. Subacute angle closure. Classification of Angle Closure 5/19/2014
Chronicity Narrow Minded The management of narrow angles in the optometric practice Acute Subacute Chronic Aaron McNulty, OD, FAAO Course Outline Classification of Angle Closure Evaluation of narrow angles
More information[TRAVOPROST] 40 MICROGRAMS/ML, EYE DROPS, SOLUTION RISK MANAGEMENT PLAN. TRAVOPR-v
[TRAVOPROST] 40 MICROGRAMS/ML, EYE DROPS, SOLUTION RISK MANAGEMENT PLAN TRAVOPR-v2-270214 VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Studies estimated that 3-6 million people
More informationand done ONE CYPASS MICRO-STENT IS ALL IT TAKES TO DELIVER ON THE PROMISE OF MIGS SAFE, CONSISTENT, LONG-TERM IOP CONTROL
FOR THE REDUCTION OF IOP IN MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA AT THE TIME OF CATARACT SURGERY and done ONE CYPASS MICRO-STENT IS ALL IT TAKES TO DELIVER ON THE PROMISE OF MIGS SAFE, CONSISTENT,
More informationGlaucoma. Glaucoma. Optic Disc Cupping
Glaucoma What is Glaucoma? Bruce James A group of diseases in which damage to the optic nerve occurs as a result of intraocualar pressure being above the physiological norm for that eye Stoke Mandeville
More informationGLAUCOMA. An Overview
GLAUCOMA An Overview Compiled by Campbell M Gold (2004) CMG Archives http://campbellmgold.com --()-- IMPORTANT The health information contained herein is not meant as a substitute for advice from your
More informationDivakar Gupta Glaucoma Fellow, Duke Eye Center 5/14/16
Divakar Gupta Glaucoma Fellow, Duke Eye Center 5/14/16 Pathophysiology of glaucoma Consider risk factors of glaucoma Understand the side effects of glaucoma medications Diagnostic testing Leading cause
More informationGlaucoma Surgical Treatments. Murray Fingeret, OD Justin Schweitzer, OD Joe Sowka, OD
Glaucoma Surgical Treatments Murray Fingeret, OD Justin Schweitzer, OD Joe Sowka, OD Disclosures Murray Fingeret Consultant Bausch & Lomb, Alcon, Allergan Justin Schweitzer Allergan, Glaukos, Bausch and
More informationOriginal Article. Abstract. Introduction. C Olali, G Malietzis, S Ahmed, E Samaila 1, M Gupta
Original Article Real-life experience study of the safety and efficacy of travoprost 0.004% / timoptol 0.50% fixed combination ophthalmic solution in intraocular pressure control C Olali, G Malietzis,
More informationCOMPARISON OF IOP LOWERING EFFICACY BRIMONIDINE-TIMOLOL VERSUS DORZOLAMIDE-TIMOLOL FIXED COMBINATION THERAPY
COMPARISON OF IOP LOWERING EFFICACY BRIMONIDINE-TIMOLOL VERSUS DORZOLAMIDE-TIMOLOL FIXED COMBINATION THERAPY DR. HIDAYATULLA KHAN, M.S. (Ophthalmology) SILVER CRESCENT EYE HOSPITAL Noorkhan Bazar, Hyderabad
More informationCURRENT TOPICS IN GLAUCOMA
CURRENT TOPICS IN GLAUCOMA JOSEPH SOWKA, OD, FAAO, DIPLOMATE NOVA SOUTHEASTERN UNIVERSITY COLLEGE OF OPTOMETRY DISCLOSURE: Joseph Sowka, OD is/ has been a Consultant/ Speaker Bureau/ Advisory Board member
More informationUnderstanding and Living with Glaucoma
Understanding and Living with Glaucoma Amanda hopes future generations won t have to live with glaucoma. Dr. Dubra s breakthrough research could mean they won t have to. I genuinely believe that a cure
More informationeffect of previous argon laser trabeculoplasty
Graefe s Arch Clin Exp Ophthalmol (2006) 244: 1073 1076 CLINICAL INVESTIGATION DOI 10.1007/s00417-005-0198-x Esther Arranz-Marquez Miguel A. Teus Effect of previous argon laser trabeculoplasty on the ocular
More informationABSTRACT INTRODUCTION
Adv Ther (2019) 36:333 343 https://doi.org/10.1007/s12325-018-0863-1 ORIGINAL RESEARCH Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis
More informationEfficacy and Tolerability of Latanoprost 0.005% in Treatment of Primary Open Angle Glaucoma (POAG)
Original Article Efficacy and Tolerability of Latanoprost.5% in Treatment of Primary Open Angle Glaucoma (POAG) Muhammad Imran Janjua, Saira Bano, Ali Raza Pak J Ophthalmol 217, Vol. 33, No. 3.....................................................................................................
More informationReason for Unscheduled Visit
Page 1 of 7 OHUN16.01 MULE: UNREASONS Reason for Unscheduled Visit * On any given page, any section started should be completed. Check all that apply: 1. Confirmation of IOP... Complete Snellen, IOP, Ocular
More informationA complicated groups of disorders characterized by optic disc and v. field changes related to a high or a statically normal IOP. It involves a study
THE GLAUCOMAS A complicated groups of disorders characterized by optic disc and v. field changes related to a high or a statically normal IOP. It involves a study of (1) IOP(2) ON head changes (3) V.field
More informationOne-year Results of a Schlemm s Canal Microstent for IOP Reduction in Open Angle Glaucoma
One-year Results of a Schlemm s Canal Microstent for IOP Reduction in Open Angle Glaucoma Thomas W. Samuelson, MD Minnesota Eye Consultants On Behalf of the HYDRUS I Investigators 1 Disclosures This study
More informationPATIENT GUIDE TO LUMIGAN 0.01%
Treatment Tracker enclosed PATIENT GUIDE TO LUMIGAN 0.01% LUMIGAN (bimatoprost ophthalmic solution) 0.01% is used for the treatment of high eye pressure, also called intraocular pressure (IOP), in people
More informationPractical approach to medical management of glaucoma DR. RATHINI LILIAN DAVID
Practical approach to medical management of glaucoma DR. RATHINI LILIAN DAVID Glaucoma is one of the major causes of visual loss worldwide. The philosophy of glaucoma management is to preserve the visual
More informationPRACTICAL APPROACH TO MEDICAL MANAGEMENT OF GLAUCOMA
PRACTICAL APPROACH TO MEDICAL MANAGEMENT OF GLAUCOMA DR. RAVI THOMAS, DR. RAJUL PARIKH, DR. SHEFALI PARIKH IJO MAY 2008 PRESENTER AT JDOS : DR. RAHUL SHUKLA T.N. SHUKLA EYE HOSPITAL TERMINOLOGY POAG: PRIMARY
More informationVisit Type (Check one)
Page 1 of 14 OHFV21.01 MULE: Page 1 Visit Type (Check one) Visit prior to 078 month visit enter visit window 0 Semi-Annual: Annual: 078 mo. 090 mo. 102 mo. 114 mo. 126 mo. 138 mo. 150 mo. 162 mo. 084 mo.
More informationGet a grip on your glaucoma Booklet 1
Information for Patients Glaucoma services Welcome! Get a grip on your glaucoma Booklet 1 Group-based Glaucoma information Course Session 1 What happens in session 1? Finding out what questions you have
More informationIt is estimated that within our
Continuing education CET Medical co-management of glaucoma Greater emphasis is being put on suitably trained optometrists to play a greater role in managing glaucoma. Aachal Kotecha and Alexander Spratt
More informationPrimary Open Angle Glaucoma (POAG) Primary Angle Closure Glaucoma (PACG) _ acute _ chronic Other causes of glaucoma (secondary glaucoma)
T H E M E : E Y E RECENT ADVANCES IN GLAUCOMA MANAGEMENT Dr VKY Yong, Dr PTK Chew INTRODUCTION Definition Glaucoma describes a group of heterogenous disorders in which progressive damage to the optic nerve
More informationNational Institute for Health and Clinical Excellence. Glaucoma. Guideline Consultation Comments Table. 29 September November 2008
National Institute for Health and Clinical Excellence Glaucoma Guideline Consultation Comments Table 29 September 2008 24 November 2008 Stat us Organisa tion Order no. Version Page no Line no/se ction
More informationOHTS Baseline/Randomization Visit: BR
Page 1 of 5 2/28/5 OHBR02.00 Coordinating Center use only Rec d... Log d... Chk d... Entr d... Checklist Check when completed Before exam, patient first completes SF-36 Quality of Life Before exam, patient
More informationM Diestelhorst, L-I Larsson,* for The European Latanoprost Fixed Combination Study Group...
199 SCIENTIFIC REPORT A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension
More informationGenerics are Cheaper and Just as Effective
Disclosures Generics are Cheaper and Just as Effective Robert L. Stamper, MD UCSF Department of Ophthalmology No current pharmaceutical industry connections Data & Safety Monitor for Cypass - Chair - Transcend
More information